Dr. Nakajima is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
1650 Orleans St. CRB1
Baltimore, MD 21287Phone+1 267-334-5333Fax+1 410-847-2063
Education & Training
Johns Hopkins UniversityFellowship, Medical Oncology, 2018 - 2020
University of Pittsburgh School of MedicineClass of 2015
Vanderbilt University Medical CenterResidency, Internal Medicine
Certifications & Licensure
MD State Medical License 2019 - 2025
DC State Medical License 2021 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 118 citationsFDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.Erica C Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S Mishra-Kalyani, Yajun Liu
Clinical Cancer Research. 2022-04-14 - 8 citationsAssessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas.Erica C. Nakajima, Michael P. Frankland, Tucker F. Johnson, S. Antic, Heidi Chen
Plos One. 2018-06-01 - 120 citationsMetabolic symbiosis in cancer: refocusing the Warburg lens.Erica C. Nakajima, Bennett Van Houten
Molecular Carcinogenesis. 2013-05-01
Press Mentions
FDA Analyses Provide Insights into First-Line Treatment for Advanced NSCLCJune 5th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
